Applied DNA Sciences: Fiscal Q1 Earnings Snapshot
- Agreement Seeks to Leverage Linea IVT Platform to Enable Kudo Bio to Offer a Differentiated mRNA Manufacturing Capability with Mitigated dsRNA and Reduced Turnaround Times -
Applied DNA Sciences: Fiscal Q4 Earnings Snapshot
- Conference Call/Webcast Scheduled for Today at 4:30 PM ET -
STONY BROOK, NY / ACCESSWIRE / December 5, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today announced...
STONY BROOK, NY / ACCESSWIRE / November 28, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced the receipt of a follow-on...
- Extension Increases Total Addressable Market to Include Both Conventional Non-Amplifying mRNA and saRNA -
- Preclinical Orders for Additional Customers Underway -
Agreement Focuses on the Accelerated Development of LNP-encapsulated LineaDNAâ„¢ Vaccines to Eliminate the Use of Plasmid DNA and Reduce the Dependence on Extreme Cold Chains of Today's mRNA Vaccines
Experienced Biopharma/Pharmaceutical Executive to Lead Implementation of cGMP-quality LineaDNAâ„¢ Capability for IVT mRNA Production